| 周 立,宋立强,程旭东,牛攀霞,王 雪.吸入激素对ACOS患者的临床疗效及对内皮细胞功能的影响[J].现代生物医学进展英文版,2017,17(30):5892-5895. |
| 吸入激素对ACOS患者的临床疗效及对内皮细胞功能的影响 |
| Clinical Efficacy of Inhaled Corticosteroids in the Treatment of Patients with ACOS and Its Influence on the Endothelial Cell Function |
| Received:March 03, 2017 Revised:March 27, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.30.021 |
| 中文关键词: 哮喘-慢阻肺重叠综合征 糖皮质激素 疗效 内皮细胞功能 |
| 英文关键词: Asthma-COPD overlap syndrome Corticosteroids Clinical efficacy Endothelial cell function |
| 基金项目: |
|
| Hits: 256 |
| Download times: 152 |
| 中文摘要: |
| 摘要 目的：探讨吸入激素治疗哮喘-慢阻肺重叠综合征(ACOS)患者的临床疗效及对内皮细胞功能的影响。方法：收集2013年3月至2016年3月在我院接受治疗的95例ACOS患者，随机分为对照组48例和观察组47例。对照组患者给予西医综合治疗，观察组患者在对照组基础上给予丙酸氟替卡松雾化吸入剂治疗。观察治疗前后两组的肺功能指标(包括最大肺活量(FVC)、1 s用力呼吸容积(FEV1)、吸气分数(IC/TLC)、残总比(RV/TLC)以及一氧化碳弥散量(DLCO))、内皮细胞功能指标(包括可溶性细胞间黏附因子(SICAM-1)、血清NO及内皮素1(ET-1))、症状评分(包括哮喘症状评分(ACT)及慢阻肺症状评分(CAT))的变化以及临床疗效。结果：观察组的临床总有效率为89.4%，显著高于对照组的77.1%(P＜0.05)。治疗后，两组的FEV1、FEV1/FVC、IC/TLC及RV/TLC均较治疗前明显改善(P＜0.05)，且观察组的FEV1、FEV1/FVC、IC/TLC、RV/TLC及DLCO改善幅度大于对照组(P＜0.05)。治疗后，两组的血清SICAM和ET-1水平均较治疗前明显降低，血清NO水平显著升高(P＜0.05)，且观察组的血清SICAM和ET-1水平显著低于对照组，血清NO水平明显高于对照组(P＜0.05)。治疗后，两组的ACT评分和CAT评分均较治疗前明显改善(P＜0.05)，且观察组的ACT评分显著高于对照组，CAT评分低于对照组(P＜0.05)。结论：吸入糖皮质激素治疗ACOS的临床疗效显著，可有效改善患者的临床症状、肺功能和内皮细胞功能。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical efficacy of inhaled corticosteroids in the treatment of patients with asthma-COPD overlap syndrome (ACOS) and its influence on the endothelial cell function. Methods: Ninety-five patients with ACOS admitted into our hospital were randomly divided into two groups. Forty-eight patients in the control group were treated with western medicine, and the observation group was treated with fluticasone propionate on the basis of control group. The lung function indexes, endothelial cell function indexes, ACT score and CAT score were compared between two groups before and after treatment, and the clinical efficacy was also compared. Results: After treatment, the effective rate of observation group was 89.4%, which was much higher than that of the control group with (77.1%, P＜0.05). The FEV1, FEV1/FVC, IC/TLC, and RV/TLC in both groups were obviously improved, and the FEV1, FEV1/FVC, IC/TLC, RV/TLC and DLCO of observation group improved much better than those of the control group(P＜0.05). And the serum SICAM and ET-1 levels of observation group after treatment were much lower than those of the control group, while the serum NO was much higher(P＜0.05). Additionally, the ACT score of observation group was significantly higher than that of the control group, while the CAT score was markedly lower(P＜0.05). Conclusion: Inhaled corticosteroids had a great capability in the treatment of patients with ACOS, which could significantly improve the clinical symptoms, lung function and endothelial cell function. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
